Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …

Aims Inflammation and organ failure have been reported to have an impact on cytochrome
P450 (CYP) 3A‐mediated clearance of midazolam in critically ill children. Our aim was to …

A variety of developmental changes is of influence on the pharmacokinetics and
pharmacodynamics of midazolam in neonatal and pediatric intensive care patients …

Background and objective Major changes in cytochrome P450 (CYP) 3A activity may be
expected in the first few months of life with, later, relatively limited changes. In this analysis …

Interventions The pharmacokinetics of midazolam and metabolites were determined during
and after a continuous infusion of midazolam (0.05–0.4 mg/kg/hr) for 3.8 hrs to 25 days …

Rationale: Various in vitro, animal, and limited human adult studies suggest a profound
inhibitory effect of inflammation and disease on cytochrome P-450 3A (CYP3A)-mediated …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Pharmacokinetic, pharmacodynamic and pharmacogenomic studies of midazolam are
currently being performed in critically ill children to find suitable dose regimens. Sensitive …

Purpose Changes in drug absorption and first-pass metabolism have been reported
throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic …